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Abstract
Background
Despite a growing body of literature on HIV service costs in sub-Saharan Africa, only a
few studies have estimated the facility-level cost of prevention of Mother-to-Child Trans-
mission (PMTCT) services, and even fewer provide insights into the variation of PMTCT
costs across facilities. In this study, we present the first empirical costs estimation of the
accelerated program for the prevention of mother-to-child transmission of HIV in Zimba-
bwe and investigate the determinants of heterogeneity of the facility-level average cost
per service. To understand such variation, we explored the association between average
costs per service and supply-and demand-side characteristics, and quality of services.
One aspect of the supply-side we explore carefully is the scale of production—which we
define as the annual number of women tested or the yearly number of HIV-positive
women on prophylaxis.
Methods
We collected rich data on the costs and PMTCT services provided by 157 health facilities
out of 699 catchment areas in five provinces in Zimbabwe for 2013. In each health facility,
we measured total costs and the number of women covered with PMTCT services and esti-
mated the average cost per woman tested and the average cost per woman on either ARV
prophylaxis or ART. We refer to these facility-level average costs per service as unitary
costs. We also collected information on potential determinants of the variation of unitary
costs. On the supply-side, we gathered data on the scale of production, staff composition
and on the types of antenatal and family planning services provided. On the demand side,
we measured the total population at the catchment area and surveyed eligible pairs of moth-
ers and infants about previous use of HIV testing and prenatal care, and on the HIV status of
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both mothers and infants. We explored the determinants of unitary cost variation using a
two-stage linear regression strategy.
Results
The average annual total cost of the PMTCT program per facility was US$16,821 (median
US$8,920). The average cost per pregnant woman tested was US$80 (median US$47),
and the average cost per HIV-positive pregnant woman initiated on ARV prophylaxis or
treatment was US$786 annually (median US$420). We found substantial heterogeneity of
unitary costs across facilities regardless of facility type. The scale of production was a strong
predictor of unitary costs variation across facilities, with a negative and statistically signifi-
cant correlation between the two variables (p<0.01).
Conclusions
These findings are the first empirical estimations of PMTCT costs in Zimbabwe. Unitary
costs were found to be heterogeneous across health facilities, with evidence consistent with
economies of scale.
Introduction
Prevention of Mother-to-Child Transmission (PMTCT) is an integral component of HIV pre-
vention programs in generalized epidemics. If implemented effectively, PMTCT has the poten-
tial to reduce HIV among infants [1], extend life expectancy and improve quality of life for
HIV-positive women [2], and reduce HIV transmission to adult men [3,4]. The roll-out of
PMTCT has already led to substantial gains globally–between 2000 and 2015, 1.6 million HIV
infections among infants were averted, and pediatric deaths were reduced by 70% [5]. Unfor-
tunately, the UNAIDS goal of virtual elimination of mother-to-child transmission (EMTCT) is
far from complete; 150,000 infants were born with HIV in 2015 [5].
The ambitious target of EMTCT initially set for 2015 as a millennium development goal
[6], requires programs to improve efficiency while maintaining quality [7–9]. Zimbabwe has
an HIV prevalence of 13.5%, 1.3 million people were living with the disease in 2016 [10]. After
expanding the PMTCT Program in 2014, 93% of the HIV infected pregnant women received
antiretroviral therapy (ART) to prevent mother-to-child-transmission (MTCT) [10]. MTCT
was estimated to account for 6.39% of all new HIV infections in children aged 0 to 14 years in
2015. Despite all efforts, only 54.9% of infants born to HIV-positive mothers received an HIV
test in the first two months of life [11].
The literature evaluating efficiency and costs of HIV services has frequently focused on pro-
gram- or national-level cost estimates, which often mask substantial heterogeneity at the clinic
level. Although there is a growing body of literature on the per-client cost of HIV services in
sub-Saharan Africa [12–21], only a handful of studies have examined the facility-level cost of
PMTCT [13, 14, 19, 21], and among those, just a few used sample sizes larger than one or two
facilities [13,14,19,21]. Thus, most of these studies estimated average costs without offering
insights on the variation of the cost per service across facilities.
Examining variation across facilities as well as both the demand- and supply-side character-
istics associated with it is critical to understand efficiency. For example, the ORPHEA study
[22] examined supply-side determinants of unitary cost variation of PMTCT programs in four
PLOS ONE Costs and economies of scale in PMTCT of HIV in Zimbabwe
PLOS ONE | https://doi.org/10.1371/journal.pone.0231527 May 20, 2020 2 / 18
countries in sub-Saharan Africa: Kenya, Rwanda, South Africa, and Zambia. The authors
found that scale (defined as the annual number of services produced) and the type of facility
(hospital or health clinic), were strongly and significantly associated with unitary cost variation
across sites [13], consistent with the existence of economies of scale–i.e., decreasing unitary
costs as the scale increases.
The objective of this paper is twofold: 1) to estimate the facility-level total costs and the aver-
age cost per woman served (unitary costs) in the Accelerated National PMTCT Program. We
measured services along two steps in the service cascade–HIV testing and counseling, and anti-
retroviral (ARV) prophylaxis or initiation of antiretroviral therapy (ART). 2) To explore deter-
minants of unitary cost variability across facilities. We investigate three potential sources of
variation. On the supply side, we explore the role of characteristics of the facilities, such as scale,
the type of facility, the staff composition, location of the facilities, and availability of other
related services nearby. On the demand side, we investigate the maternal HIV prevalence,
MTCT rates, HIV free infant survival rate at 9–18 months, and uptake of HIV testing during
pregnancy—all at the catchment area level. Finally, we also explore whether quality—as mea-
sured by the completeness of family planning, antenatal, and PMTCT services—is associated
with unitary costs variation. We use data from a cross-sectional survey of 157 randomly selected
facilities offering PMTCT services and their catchment areas, in five provinces in Zimbabwe.
Methods
We analyzed 2013 data from the impact evaluation of Zimbabwe’s Accelerated National
PMTCT Program. The project was funded by the Children’s Investment Fund Foundation
together with Elizabeth Glaser Pediatric AIDS Foundation Zimbabwe. The impact evaluation
combines cross-sectional surveys to determine the impact of Zimbabwe’s EMTCT program on
MTCT as well as HIV-free survival among children aged 9 to 18 months. Previous results from
this project have analyzed different aspects of the Program. For example, McCoy et al. (2015)
examined the uptake of services and determined the factors associated with MTCT, maternal
ART, and ARV prophylaxis [23]. Buzdugan et al. (2015) estimated HIV-free infant survival
and MTCT rates [24], and Buzdugan et al. (2016) evaluated the impact of Option A on HIV-
free infant survival and MTCT [25]. In this paper, we provide the baseline assessment of the
efficiency of the PMTCT Program, using 2013 data from household and facility surveys, col-
lected in 2014.
Theoretical framework
In this analysis, we adopt a microeconomic lens to analyze efficiency. In the case of PMTCT
services supplied by government facilities, scale (the annual number of PMTCT services pro-
vided) cannot be assumed to be exogenous–as is typically the case in the standard microeco-
nomic model. The level of output produced by a health facility is determined as much by
decisions made in the facilities, as by decisions made by patients. Health facilities choose not
only how to allocate their resources, but also when to offer services, the quality of those ser-
vices, and in general the type of experience they provide to patients. The results from those
decisions in turn influence patients, who decide whether to demand those services or not, sub-
ject to their budget and other financial and non-financial constraints; and where to demand
those services, constrained by the availability of nearby services. Thus, scale, measured as the
number of services provided, is the result of decisions on the supply side by health providers,
as well as decisions on the demand side by patients.
Two critical elements on the demand side, which may influence efficiency, are size and
complexity. Higher demand potentially leads to an expansion of scale, which in turn is
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associated with lower unitary costs because fixed costs are distributed across more patients
and also because human resources operate closer to full capacity (less idle time). This gain in
efficiency as a result of larger scale is known as economies of scale. On the other hand, popula-
tions with more complex needs may increase costs. For example, the most expensive drug
combinations that include more than three different elements are recommended only to
patients in the most advanced stage of the disease [26], or high-risk pregnancies referred to
hospitals require more and costlier resources, including staff, drugs, and laboratory tests.
In the analysis presented in this paper, we used both types of characteristics of the demand–
size and complexity, and we use the size of population on clinics’ catchment areas as an instru-
ment for the endogenous measure of scale. For proxies of demand complexity, we used mater-
nal HIV prevalence; rate of mother-to-child transmission of HIV; rate of HIV-free infant
survival; and uptake of HIV testing during pregnancy.
Description of the intervention
In 2010, the World Health Organization issued guidelines for EMTCT based on the CD4
count of HIV positive mothers. CD4 T-cells are a type of white cell part of the immune system
that fights bacteria, viruses, etc. The CD4 count is a test that measures the number of T-cells to
assess the immune system’s health. HIV-infected pregnant women with immune damage of
less than 350 CD4 cells, were eligible for lifelong antiretroviral treatment (ART). On the other
hand, pregnant women ineligible for ART (CD4>350) were recommended to receive one of
two options of prophylactic regimens: Option A consisted of starting at 14 weeks of pregnancy
through 7 days postpartum; or Option B, an ARV preventive regime beginning at 14 weeks of
pregnancy and continuing until weaning [27]. In 2013 and 2015, WHO revised these guide-
lines and rolled out Option B+, which recommended that all HIV infected pregnant women
should receive lifelong ARV treatment regardless of CD4 count starting as soon as diagnosed
[28, 29].
The Accelerated National PMTCT Program was implemented in 2011 by Zimbabwe’s Min-
istry of Health and Child Care (MoHCC) based on PMTCT Option A from WHO’s 2010
guidelines. Zimbabwe then switched to Option B+ in late 2013. [27, 30, 31]. Thus, at the time
covered by our surveys (2012–2013), pregnant women were not exposed to Option B+. Under
Option A, non-eligible HIV-positive women received ARV prophylaxis starting at 14 weeks of
pregnancy through 7 days postpartum. HIV-infected pregnant women with CD4<350,
regardless of symptoms, were eligible to receive lifelong ART. The recommended ARV regi-
men was Zidovudine (AZT) twice daily for the mother, and prophylaxis with either AZT or
Nevirapine (NVP) for six weeks after birth if the mother was not breastfeeding the infant. If
the infant was breastfeeding, daily NVP infant prophylaxis continued for one week after the
end of the breastfeeding period [27, 30].
Sampling strategy
The sampling strategy followed a two-stage process. First, we randomly selected 157 out of 699
health facilities from five provinces that provided PMTCT services for the entirety of 2013 in
Zimbabwe: Harare, Mashonaland West, Mashonaland Central, Manicaland, and Matabeleland
South. These provinces were selected to include three of the four largest cities in Zimbabwe,
rural communities with high and low HIV prevalence, representation of both major ethnic
groups in Zimbabwe (Shona and Ndebele), and areas where detailed monitoring-and-evalua-
tion data were being collected [24]. Second, in each catchment area–defined as a neighborhood
of a 10-km radius around each facility, we identified 21,205 eligible pairs of mothers/caregivers
aged 16 or older and infants (born 9–18 months before the survey). We randomly selected a
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fraction of all mother-infant pairs with the aim of recruiting 50 from each catchment area to
participate in the study. Overall, 9,087 mother-infant pairs did. The sampling strategy was pre-
viously described in more detail [23, 24, 25, 32].
We estimated a sample size of 157 PMTCT clinic catchment areas. We expected to identify
an average of 190 infants aged 9–18 months per catchment area of PMTCT clinic, assuming
10.5 living infants aged 9–18 months per 100 households and approximately 1,800 households
per catchment area of a PMTCT clinic. If we identified all eligible infants and enrolled 1 in
every four eligible infants, this would result in 47.5 living infants aged 9–18 months per catch-
ment area. Our estimated sample size for the baseline community survey is approximately
7,800 infants (7,442 alive and 353 deceased) and their mothers or caregivers from 157 PMTCT
catchment areas. However, those initial sample size calculations were revised upwards after
incorporating new data on variability in the number of eligible mother-infant pairs and the
underlying HIV prevalence across catchment areas. The overall size of the population
recruited increasing from an estimated 7,800 to 9,087.
Data collection and measurement
Facility-level characteristics. The survey team administered a short questionnaire in each
of the 157 health facilities. All data were collected on paper by a trained data collector and later
entered into an Access™ database by a data entry operator. Researchers conducted periodic
reviews of the data for completeness and consistency.
We collected data on the type of facility visited, according to Zimbabwe’s classification of
health centers. Our sample included ten different types of health facilities; however, for the
analysis, we grouped them into hospitals and non-hospitals (See S 1 for a detailed description
of the different types of facilities). PMTCT services costs in hospitals tend to be higher. One
important reason is that hospitals are more complex facilities, given that they provide not only
outpatient but also inpatient services. Hospitals also tend to include more specialized, therefore
higher paid medical staff. Because of these reasons, one hypothesis regarding our study is that
hospitals are less flexible in terms of allocation of resources compared to clinics. This lack of
adaptability could decrease efficiency and increase costs.
Costs. We adopted the perspective of service providers on the analysis. Therefore, we did
not measure patients’ expenditures, such as out-of-pocket fees or transportation expenses.
Moreover, only 4% of the women in the sample declared to have paid for PMTCT services.
We used a retrospective microcosting approach to measure monthly quantities and prices
of three essential input categories: personnel, ARV drugs, and HIV tests kits. These categories
comprise the largest share of the total costs of PMTCT services, according to previous studies
[13, 14, 33]. We did not include other inputs involved in the provision of PMTCT, which typi-
cally represent less than 10% of the total costs [13, 14, 33], such as capital costs, training, super-
vision, and other recurrent costs.
We valued all inputs at market prices, including donations, adopting an economic rather
than a financial costing approach. Given that all the units in our sample are government clin-
ics, there is no variation in input prices or salaries across facilities. The Ministry of Health cen-
trally establishes wages based on cadre categories and purchases all essential inputs (drugs and
tests) through centralized procurement processes. Thus, the variation in unitary costs across
facilities reflects differences in efficiency; the ability of clinics to produce services, given the
resources at their disposal and given the demand characteristics they face.
We collected data on the total annual outputs produced along two steps in the PMTCT ser-
vice cascade–HIV testing and ARV/ART initiation. When these data were not available at the
facilities, we collected them from the district health information system.
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We also assessed the time allocation of personnel providing PMTCT services through inter-
views with five randomly selected providers per facility, in which we asked them to report the
time they spent working on PMTCT every day of the previous week. Self-reported time alloca-
tion to specific tasks has been found to overestimate effort allocated to particular services [34].
We attempted to minimize this potential bias in three ways. First, instead of asking about a
“typical week” or a “typical year” which is a common wording for these questions, we asked
about the “last week”; this would spare the respondent any mental calculation and make it eas-
ier to remember. Secondly, we clarified the purpose of the questions, which was not part of a
performance evaluation. Finally, we assured respondents that the information they provided
would be used only in statistical analyses at the facility level.
We categorized staff in three types of nurses (primary, general, and sisters in charge) and
one broad category of health personnel which includes counselors, health promotion officers
and other support staff (S 2). "Primary care nurse" was the category with the lowest average sal-
ary, and the second most common in the sample, after "general nurse."
Quality. Additionally, we collected information on the scope and comprehensiveness of
PMTCT and other related maternal services provided at the facilities, as a proxy for quality.
Process quality, which measures the extent to which providers follow the processes outlined or
explicitly listed in official guidelines, has been used previously as an indicator of the quality of
health care [35]. For example, Marley et al. (2004) found that process quality is as good as clini-
cal quality in predicting patient satisfaction in hospitals in the U.S. [36]. Rademakers (2011)
found that processes followed in hospitals in the Netherlands explained most of the variation
of the patients’ evaluation of quality of surgery and other interventions [37]. Meehan (1997)
assessed the quality of care for Medicare patients hospitalized with pneumonia and found an
association between the process of care and mortality [38].
There is also evidence from less affluent countries; Das and Gertler (2007) document prac-
tice quality on six different studies in five low- and middle-income countries. They provide
evidence on the large effect of process quality on health outcomes compared to those of avail-
ability or structural quality [34]. Das and Hammer (2014) argue that access to healthcare is not
the main problem in low-income countries anymore [35]. They provide evidence suggesting
that process quality to be the real issue.
We collected information on the availability of services offered at the facilities as a proxy for
process quality. Specifically, we asked which services they provided out of a comprehensive list
of family planning, ANC and ART/ARV prophylaxis services recommended by the govern-
ment. For example, whether contraception services were offered during antenatal visits, after
labor and delivery, during postnatal care visits, and during child immunization visits, and con-
structed a variable index for contraception services based on the number of recommended
care practices undertaken in the facility. We computed similar variables for antenatal services
and ARV prophylaxis or ART (see S 2 for the complete list of recommended processes used
for each indicator).
Demand-side characteristics. We also collected data on some characteristics of the
demand as proxies for size and complexity. We surveyed mothers about their HIV status and
estimated the maternal HIV prevalence; the rate of mother-to-child transmission of HIV; the
rate of HIV-free infant survival; and the uptake of HIV testing during pregnancy. Finally, we
asked each facility for the estimated total size of the population they served. All of these vari-
ables refer to the catchment area level.
The survey team administered a household-level survey in 2014 to the selected sample of
9,087 mother-infant pairs. Mothers or caregivers 16 years old and older and their infants born
between 9 and 18 months before the interview (alive or deceased), were eligible to participate
in the study. The data enumerator sought informed consent to complete the questionnaire and
PLOS ONE Costs and economies of scale in PMTCT of HIV in Zimbabwe
PLOS ONE | https://doi.org/10.1371/journal.pone.0231527 May 20, 2020 6 / 18
to collect dried blood samples (DBS) for HIV testing from the mother and her eligible infant.
The mother could consent to participate in both, neither, or either the questionnaire and DBS.
The questionnaire was administered using a Personal Digital Assistant (PDA) and captured
the mother’s demographic characteristics, her experience with ANC and HIV testing, and
more specifically, her experience with ANC during the pregnancy for the eligible child [31].
Finally, all living biological mothers and infants provided DBS for HIV testing.
Analysis
Estimation of costs. We calculated the total annual costs of PMTCT services for each
facility as the sum of personnel and recurrent inputs costs used in 2013, as follows:
TCj ¼
X
hij � wi þ
X
xjk � pk
Where TCj denotes total costs of facility j. Personnel costs were estimated by the sum of the
number of hours hij each type of personnel i in a facility j worked on PMTCT services, multi-
plied by the hourly wage wi corresponding to provider type i. Recurrent costs (ART drugs and
HIV test kits) were calculated as the sum of the k number of goods xjk multiplied by their
prices pk.
Then, the facility-level average unitary costs per output, ACjl along the cascade were defined
as:
ACjl ¼
TCj
qj l
Where qjl is the 2013 annual number of outputs produced by facility j along the cascade indica-
tor l, where l = 1 for number of pregnant women tested, l = 2 for HIV positive women on ARV
prophylaxis or treatment.
The objective of this costing approach is to explore the efficiency of the PMTCT program
by looking at the heterogeneity of "unitary costs" across implementers. This approach provides
insight on the efficiency of the program at the facility level and across the service cascade.
Variation of unitary costs. We explored the facility-level variation of the unitary costs of
PMTCT at two steps of the service cascade: HIV testing and ARV prophylaxis or ART. First,
we present the dispersion of average unitary costs by type of facility to describe the variation
across facilities. Then, we explore three potential determinants of the heterogeneity in unitary
costs. On the supply side, we investigated the role of scale, staff categories, and facility type. On
the demand side, we included in the analysis the prevalence of maternal HIV, the rates of
mother-to-child transmission of HIV and HIV-free infant survival at 9–18 months, and the
levels of uptake of HIV testing during pregnancy. Finally, we analyzed the role of the quality of
services.
Analytic strategy. We were interested in identifying how supply- and demand-side char-
acteristics influence the variation of unitary costs across facilities, and in particular the role of
the scale of PMTCT services. However, a simple linear regression could yield a biased parame-
ter due to endogeneity bias since there may be unobservable or omitted characteristics simulta-
neously explaining costs and scale. To minimize this potential bias, we apply a two-stage least
square model using demand size, measured by the size of the population at the catchment-area
level, as an instrumental variable (IV). With this approach, we estimated first, the association
between demand size and scale; and, second, the effect of scale and other supply-side charac-
teristics on the unitary costs of PMTCT services.
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The second stage regression model is specified as follows:
yi ¼ a0 þ px
�
i þ gsssi þ ddddi þ Zqqqi þ εi ð1Þ
Where yi represents the log-transformed unitary costs of PMTCT services (for each step of the
cascade): the average cost per pregnant woman tested for HIV in facility i, or the average cost
of an HIV-infected pregnant woman on ARV prophylaxis or ART in facility i. Scale is the
endogenous variable represented by xi, ssi is a vector of s supply characteristics including a
binary variable for type of facility (hospital or non-hospital), the proportion of primary care
nurses with respect to the other types of staff; ddi is a vector of d demand-side characteristics,
qqi is a vector of q process quality variables; and εi is the residual term.
In the first stage (Eq 2), we regress the endogenous variable on the exogenous variables in
the model including our instrument, the log-transformed size of the population in the catch-
ment area (zi) to obtain adjusted values of x (x
�) and use them in the second stage of the analy-
sis (Eq 1) to obtain unbiased estimates of y.
x�i ¼ zipz þ p0 þ p1sssi þ p2dddi þ p3qqqi þ vi ð2Þ
Although the validity of an instrumental variable cannot be fully statistically tested, we com-
puted the first stage F-statistic to verify the condition of the Stock-Yogo critical values [39]. To
test for endogeneity, we implemented the Durbin-Wu-Hausman test with the null hypothesis of
exogeneity. However, we also verified the two conditions for the instrumental variable model to
be valid. First, we descriptively examined the association between the instrumental variable
‘population size’ and the endogenous variable ‘scale’ of PMTCT services production (see S3 and
S4 Files). We found a meaningful and statistically significant association. Secondly, we explored
the association between costs and the size of the population and found no statistically significant
correlation, suggesting the instrumental variable (population size) influences the dependent var-
iable only through scale. We acknowledge that different channels could also be associated with
population size and costs. For example, more populated areas concentrate more skilled provid-
ers which could translate into higher staff costs or more efficient use of resources. There appears
to be a low correlation between higher skilled providers and costs; however, this is not statisti-
cally significant. Nevertheless, we have addressed this possible source of bias by controlling for
staff composition in all our regressions. Overall, our results are consistent with our assumption
that the area population affects costs only through scale, rendering validity to our approach.
In addition to the IV model, we estimated two naïve OLS models, one for each of the two stages
of the PMTCT cascade. These OLS models regressed log-transformed costs on the log-trans-
formed scale and controlled for the same supply-side characteristics and quality/completeness, as
the IV models. We used robust standard errors and province fixed effects in all regressions.
Human subjects research. This research was approved by the Institutional Review Board
of the University of California Berkeley.
Results
Costs of PMTCT services
Table 1 shows descriptive statistics of unitary costs, supply- and demand-side, and quality indi-
cators. From the sample of 157 health facilities, 17% were hospitals. Approximately half of the
staff were primary care nurses. On average, health facilities offered three out of four recom-
mended ARV prophylaxis or treatment practices (S2 File), 5.5 out of six ANC services, and ten
out of 12 contraceptive services. The average annual number of PMTCT clients tested per facil-
ity was 305 (median 186), and the yearly average number of HIV-positive women receiving
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ART or ARV prophylaxis for MTCT per facility was 33 (median, 19). The average annual total
cost of PMTCT services was $16,821 (median, $8,920) in153 health facilities with complete
information. Total yearly costs varied according to the type of facility; in hospitals, the average
was $20,786, and in non-hospitals, it was $16,162.
The average unitary cost per pregnant woman tested was $80 (median, $47), and the average
cost per HIV-infected pregnant woman receiving ART or ARV prophylaxis was $786 (median,
$420) per year. The former ranged from $12 to $528, and the latter from $61 to $5,018.
This variation in unitary costs across facilities is further illustrated in Fig 1. There are sub-
stantial differences in the dispersion of costs between hospitals and non-hospitals. We find var-
iability of two and three orders of magnitude across facilities in both the cost per woman
tested and the cost per woman on ARV/ART, regardless of facility type.
Healthcare costs data is usually skewed. To implement linear regression models, we trans-
formed the data to natural logarithms and decrease skewness. This kind of transformation is a
common approach in applied econometrics. Fig 2, illustrates the distribution of the unitary costs.
Two-stage least squares estimation of the determinants of unitary costs
Table 2 shows the results of a two-stage least squares (2SLS) model estimation of the impact of
scale on unitary costs, with the size of the population in the catchment area as an instrumental
Table 1. Description of the sample. Annual facility-level costs, scale and other supply-side characteristics.
N mean sd min p50 max
Supply-side characteristics
Proportion of hospitals 154 0.17 0.37 0 0 1
Proportion of staff that are primary care nurses 154 0.49 0.31 0 0.5 1
Proportion of facilities in urban areas 157 0.05 0.22 0 0 1
Catchment areas intersect 150 0.13 0.33 0 0 1
Demand-side characteristics
Total population by facility 149 10,777 15,621 300 7,589 130,657
Maternal HIV prevalence 153 14.75 7.35 0 14.29 37.33
MTCT, 9–18 months 151 5.05 8.67 0 0 50
HIV-free infant survival, 9–18 months 151 94.90 8.69 50 100 100
Uptake of HIV testing during pregnancy 153 92.62 7.25 54.76 94.34 100
Quality/Completeness�
ARV prophylaxis/ART services offered by facility 160 3.01 1.30 0 4 4
ANC services offered by facility 160 5.53 1.07 0 6 6
Contraception services offered by facility 160 10.03 2.20 0 11 12
Scale of production
Number of women tested for HIV 137 305 727 0 186 8,365
Number of women on ARV prophylaxis/ART 137 33 49 0 19 319
Total costs (USD)
Per facility 153 16,821 41,262 1,128 8,920 432,998
Per hospital 24 20,786 16,012 5,922 15,786 74,208
Per non-hospital health facility 128 16,162 44,575 1,128 8,422 432,998
Average unitary costs
Per woman tested for HIV 135 80 83 12 47 528
Per woman on ARV prophylaxis/ART 127 786 892 61 420 5,018
�Quality/completeness variables are calculated as the number of recommended practices offered in a facility. (See S1 File)
https://doi.org/10.1371/journal.pone.0231527.t001
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variable. Columns (1) and (2) present the results of the naïve OLS models. Columns (3) and
(5) show the first-stage estimates of both 2SLS models, which show a significant association
between the total population in the catchment area and scale. For every 10% increase in popu-
lation size, there is an average 6.6% increase in the number of women tested, and an average
6% increase in the number of women on ART/ARV prophylaxis.
Total population size in the catchment area satisfies the Stock-Yogo test for weak instru-
ments as the F statistic for significance of the instruments in the first stage exceeds 10. The
Durbin-Wu-Hausman test for over-identifying restrictions is satisfied only for cost per
woman in ART but not for cost per woman tested implying that scale is not endogenous in
regression 4 and OLS model 1 is valid. Table 2 provides both the F and DWH statistics.
Second-stage estimates of the 2SLS model show a strong negative relationship between
scale and unitary costs—Columns (4) and (6)—with slightly smaller coefficients than those
from the naïve OLS estimations, which illustrates the relatively small magnitude of the bias
introduced by the naïve models. According to the 2SLS results, an increase of 10% annual
number of women served translated into an average 5.8% decrease in the cost per woman
tested, and a 4.2% decrease in the cost per woman initiated on ART/ARV. Fig 3 illustrates the
inverse relationship between costs and scale graphically.
Our identification strategy assumes that size of the population at the catchment area is a
valid instrument, which means it only affects costs through scale. In order to test this
assumption, we consider other paths through which population size may affect costs. For
example, whether a catchment area is an urban area or not may affects costs. We tested this
possibility and found that urbanicity and HIV test costs or ART costs are not correlated
(0.01 and -0.01 respectively). Another reason for population size influencing costs other by
scale could be that health professionals prefer to live in more populated areas, most likely
Fig 1. Dispersion of unitary costs by facility type.
https://doi.org/10.1371/journal.pone.0231527.g001
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urban areas, so there might be more competition to be relocated there. This may cause
more concentration of higher skilled health providers in more populated areas which may
increase the cost of health services. We explored this hypothesis and found that facilities in
more populated areas have higher concentration of high skilled health providers (midwives
0.22, senior registered general nurses 0.25); and low concentration of low skilled providers
(nurse aids -0.32). However, there is no association between proportion of skilled workers
in the facility and costs (S4 File).
We further explore the relationship of costs and scale with non-linear OLS models. In
Table 3 we present the linear OLS model previously used and add a quadratic and cubic
model. Column (3) suggests a cubic relationship between cost per woman tested and scale.
However, columns (4) to (6) do not seem to indicate nonlinear relationship between cost per
woman in ART and scale. Columns (4) and (5) show a strong linear relationship between cost
and scale, while Column (6) shows a weak relationship of a higher degree polynomial.
Results from Tables 2 and 3 suggest that there is a linear relationship between cost per
woman on ART and scale that is endogenous and can be instrumented with population size at
the catchment area level. Moreover, there is a polynomial relationship of degree three between
cost per woman tested and scale.
The data also confirmed the relationship between personnel categories and unitary costs;
with lower costs linked to a higher proportion of primary care nurses. We found a statistical
association between the type of facility and lower costs per woman tested. There was no signifi-
cant difference in unitary costs per woman on ART between hospitals and non-hospitals, and
we found no association between process quality of reproductive and maternal services and
unitary costs.
Fig 2. Histograms of unitary costs.
https://doi.org/10.1371/journal.pone.0231527.g002
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On the demand side, we found a significant association between maternal HIV prevalence
and the proportion of women tested for HIV in prenatal care with higher HIV testing costs.
Table 2. OLS and 2SLS estimations of the determinants of unitary costs along two steps in the PMTCT service cascade.
(1) (2) (3) (4) (5) (6)
Cost per woman tested
(ln)
Cost per woman in ART
(ln)
Women
tested
Cost per woman
tested
Women in
ART
Cost per woman in
ART
VARIABLES 1st 2nd 1st 2nd
Supply side characteristics
Scale (ln) -0.61��� -0.73��� -0.58��� -0.42��
(0.07) (0.08) (0.11) (0.18)
Hospital (0,1) 0.43�� 0.36� 0.32� 0.42�� 0.55�� 0.14
(0.17) (0.18) (0.19) (0.17) (0.26) (0.22)
Primary care nurse (%) -0.40� -0.40 -0.18 -0.46�� -0.56 -0.27
(0.23) (0.28) (0.28) (0.20) (0.36) (0.27)
Urban area 0.53 1.32��� 0.69�� 0.18 0.45 0.76
(0.34) (0.47) (0.31) (0.32) (0.54) (0.51)
CD4 testing services within
catchment area
-0.31�� -0.37�� -0.42�� -0.29�� -0.20 -0.31�
(0.14) (0.15) (0.16) (0.13) (0.19) (0.16)
Demand side characteristics
Maternal HIV prevalence 0.008 0.001 -0.008 0.01 0.01 0.001
(0.008) (0.008) (0.009) (0.008) (0.01) (0.009)
MTCT, 9–18 months -0.04 0.01 0.02 -0.09��� 0.18�� -0.07
(0.05) (0.08) (0.03) (0.03) (0.07) (0.08)
HIV-free infant survival, 9–18
months
-0.05 0.006 0.02 -0.09��� 0.19��� -0.08
(0.05) (0.08) (0.03) (0.03) (0.07) (0.08)
Uptake of HIV testing during
pregnancy
0.009 0.003 0.009 0.009 0.02�� 0.0002
(0.007) (0.008) (0.008) (0.007) (0.01) (0.01)
Process quality
Offers contraception services 0.009 -0.006 0.02 -0.01 0.08 -0.06
(0.04) (0.05) (0.05) (0.04) (0.06) (0.06)
Offers ARV prophylaxis 0.04 0.18 0.25��� 0.01 0.01 0.09
(0.09) (0.14) (0.09) (0.10) (0.12) (0.13)
Offers ANC services 0.01 0.009 0.00005 0.01 0.01 0.01
(0.04) (0.04) (0.03) (0.03) (0.03) (0.03)
Instrument
Population in catchment area 0.66��� 0.60���
(0.09) (0.16)
Constant 11.53� 6.78 -5.76 16.36��� -24.10�� 15.59�
(5.86) (8.43) (3.61) (3.87) (7.35) (8.57)
Observations 130 122 127 127 118 118
Adj R-squared 0.50 0.47 0.53 0.59 0.38 0.49
Robust IV F-stat 47.21 13.94
Durbin pval 0.51 0.04
Standard errors in parentheses
��� p<0.01,
�� p<0.05,
� p<0.1
https://doi.org/10.1371/journal.pone.0231527.t002
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Discussion
Using data from a cross-sectional survey of 157 randomly selected health facilities offering
PMTCT services in Zimbabwe, in this paper we presented the first empirical estimations of the
PMTCT program costs along the service cascade in Zimbabwe, adopting the perspective of the
government. We found that the average annual total cost of PMTCT per facility was $16,821
(median, $8,920). The type of facility is a significant predictor, with an average of $20,786 in
hospitals and $16,162 in non-hospitals. The average annual cost per service was $80 per preg-
nant woman tested for HIV (median, $47), and $786 per HIV-infected pregnant woman on
ARV prophylaxis or ART (median, $420).
Our results are comparable to previously published estimates. In a study conducted in four
African countries in 2013 [13], unitary costs ranged from $18 per pregnant woman tested in
Rwanda to $89 in South Africa; and from $ 704 per woman in antiretroviral prophylaxis in
South Africa to $ 2,314 in Rwanda. A similar study conducted in Nigeria [14], found that the
facility-level unitary costs per woman tested, per HIV-positive woman diagnosed, and per
HIV-positive woman on prophylaxis were $46, $2,932, and $3,647, respectively. In a systematic
review of HIV treatment and PMTCT costs for low and middle-income countries [12], the
median ART cost per patient per year in low-income countries was $792; while, for middle-
income countries, the median was $932.
A unique feature of our study is the large sample size of facilities included in the analysis,
which allowed us to analyze the technical efficiency of PMTCT service provision in Zimbabwe.
Our results demonstrate the high variability of facility-level unitary costs, a finding consistent
with previous research. For example, a study that identified significant heterogeneity in
Fig 3. Unitary costs along the cascade and scale.
https://doi.org/10.1371/journal.pone.0231527.g003
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PMTCT unitary costs in Kenya, Nigeria, Rwanda, South Africa, and Zambia with sample size
similar to ours, and suggested potential gains from more efficient delivery of services [13, 14].
In this study, we explored the relationship between supply-side characteristics, demand size
and complexity, and unitary costs. Scale of services was the primary predictor of unitary cost
variability, a link that has been documented previously [13, 14, 21, 40]. A review of economic
methodologies that study the relationship between HIV/AIDS intervention costs and scale
Table 3. Non-linear OLS models.
(1) (2) (3) (4) (5) (6)
Cost per woman
tested (ln)
Cost per woman
tested (ln)
Cost per woman
tested (ln)
Cost per woman in
ART (ln)
Cost per woman in
ART (ln)
Cost per woman in
ART (ln)VARIABLES
Supply side characteristics
Scale (ln) -0.58��� -0.42 3.19��� -0.72��� -1.05��� 0.19
(0.07) (0.46) (0.76) (0.07) (0.37) (0.64)
Scale squared (ln) -0.01 -0.72��� 0.06 -0.42�
(0.04) (0.13) (0.06) (0.23)
Scale cubic (ln) 0.04��� 0.055��
(0.007) (0.02)
Hospital (0,1) 0.39�� 0.40�� 0.35� 0.33� 0.29 0.23
(0.18) (0.18) (0.17) (0.18) (0.18) (0.18)
Primary care nurse (%) -0.36 -0.37 -0.32 -0.34 -0.25 -0.31
(0.23) (0.23) (0.22) (0.27) (0.30) (0.31)
Urban area 0.45 0.50 0.16 1.26�� 1.00�� 0.68�
(0.34) (0.33) (0.27) (0.48) (0.46) (0.40)
Demand side characteristics
Maternal HIV prevalence 0.009 0.01 0.01 0.001 -0.001 -0.001
(0.007) (0.007) (0.007) (0.008) (0.008) (0.008)
MTCT, 9–18 months -0.04 -0.03 -0.12��� 0.01 -0.03 -0.09
(0.05) (0.05) (0.04) (0.08) (0.08) (0.07)
HIV-free infant survival, 9–18
months
-0.05 -0.04 -0.12��� 0.009 -0.03 -0.09
(0.05) (0.05) (0.03) (0.08) (0.08) (0.07)
Uptake of HIV testing during
pregnancy
0.008 0.008 0.008 0.001 0.002 0.002
(0.007) (0.007) (0.006) (0.008) (0.008) (0.007)
Process quality
Offers contraception services -0.001 0.001 0.007 -0.02 -0.02 -0.03
(0.04) (0.04) (0.04) (0.05) (0.05) (0.05)
Offers ARV prophylaxis 0.007 0.001 -0.06 0.16 0.15 0.13
(0.10) (0.10) (0.09) (0.14) (0.14) (0.14)
Offers ANC services 0.009 0.012 0.02 0.003 -0.003 -0.004
(0.03) (0.03) (0.03) (0.04) (0.04) (0.04)
Constant 11.38� 10.21� 12.40��� 6.40 11.64 17.20��
(5.88) (5.89) (4.45) (8.54) (9.09) (8.11)
Observations 130 130 130 122 122 122
R-squared 0.49 0.48 0.53 0.46 0.46 0.48
Robust standard errors in parentheses
��� p<0.01,
�� p<0.05,
� p<0.1
https://doi.org/10.1371/journal.pone.0231527.t003
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found that scale variation explains between 26% and 70% of cost variation across locations for
similar interventions [40]. In Nigeria, a study found negative associations between scale and
costs, implying decreasing rates of economies of scale [14]. Another study on six types of HIV
prevention interventions in five low and middle-income countries found that efficiency
increased with scale across all countries and interventions [21]. Our results predicted an aver-
age reduction of 6.1% in the cost per woman tested for HIV, and of 4.2% in the cost per
woman on ART or ARV prophylaxis, for every 10% increase in scale.
Another supply-side determinant of efficiency identified in this study was the type of facil-
ity. Hospitals were found to be 43% more expensive for HIV testing than clinics, on average.
While our data do not allow us to identify the reasons behind this difference, one hypothesis is
that relatively sophisticated facilities necessarily provide this simple service at a higher cost
than clinics. Another possibility is that the quality of testing services in hospitals is higher with
better content, longer duration, and more skilled labor. Our data show that facilities relying
more heavily on primary care nurses were 40% less expensive for HIV testing than other using
personnel with higher salaries. We did not see a correlation between the quality of services and
unitary costs. We found no difference between hospitals and non-hospitals in the cost per
woman on ARV prophylaxis or ART.
On the demand side, our results did not suggest a relationship between the complexity of
the demand and unitary costs. However, we did observe a strong correlation between demand
size and scale. Our results predicted a 6% increase in the number of women on ART for every
10% increase in population size.
In this study, we use instrumental variables as a strategy to estimate the effect of scale on
unitary costs of PMTCT services. As mentioned before, previous studies have documented
this relationship and found evidence consistent with the existence of economies of scale. How-
ever, to our knowledge, this is the first study that uses an econometric strategy to disentangle
the endogenous relationship between scale and unitary costs. We instrumented scale with pop-
ulation size at the facility catchment area level. We found that while population and scale are
strongly correlated, population and costs are not, which is consistent with the assumptions of
our identification strategy. Our results suggest then the presence of economies of scale in the
production of PMTCT services in Zimbabwe.
Readers should interpret our results in light of the limitations of the study. First, the data
collected on time allocation by staff was self-reported, which has been documented to be
biased upwards when compared to more reliable, observation-based methods, such as time-
motion studies [13, 14, 22, 41]. Therefore, our approach could lead to an overestimation of
unitary costs, however probably not an overestimation of unitary cost variation across facili-
ties, since we used the same method across the whole sample.
Second, our measurement of costs included the major costs categories, namely, staff, ARV
drugs, and HIV tests kits. We left out costs associated with recurrent services, such as utilities
and fuel, capital costs like buildings and equipment, and costs related to supervision and train-
ing. While the relative contribution of these categories to total PMTCT costs has been docu-
mented to be less than 10% [13, 14, 33], our estimates provide a lower-bound assessment,
nevertheless.
Our indices of process quality focus on completeness or comprehensiveness of services.
Although previous studies have found associations between this type of quality proxy and
health outcomes and patient’s perceptions [36, 37, 38], it captures only one dimension of qual-
ity. We did not measure other aspects such as structural quality or health outcomes. Therefore,
our results on the effects of process quality on efficiency are not conclusive.
Although the validity of an instrumental variable cannot be fully statistically tested, we tried
to verify the two conditions for the instrumental variable model to be valid. We found a strong
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correlation between population and scale and explored potential channels through which pop-
ulation can affect costs other than scale and did not find any. These results support our choice
of instrumental variable.
We found a strong relationship between the scale of services and unitary costs, consistent
with the existence of economies of scale and robust after correcting for potential endogeneity
bias. However, the policy implication of this finding should not be to provide PMTCT services
only in large facilities or in catchment areas with large populations. This interpretation could
have undesirable equity consequences on communities in smaller locations. The policy impli-
cation should be instead to focus efforts on understanding the differences between inefficient
and efficient small facilities—as well as between inefficient and efficient large facilities. In
other words, efforts on identifying other determinants of efficiency while accounting for scale
effects would be valuable. For example, our results suggest that less sophisticated facilities and
staff composition also have efficiency implications. Another policy consequence of the scale
effect is for programs to make the appropriate budget planning to adjust for the higher cost
per patient expected in smaller facilities. Finally, HIV programs could also consider merging
small facilities when doing so could represent gains in efficiency without compromising access
to services by the population.
Despite the limitations of the study, our results provide robust cost estimates of the
PMTCT program in Zimbabwe using data from a cross-sectional survey of 157 randomly
selected health facilities. Furthermore, we found that a large proportion of heterogeneity in
unitary costs is explained by scale, which, in turn, is determined by population size in the
catchment area. Although our results identify strong associations and control for potential
biases, the nature of our data does not allow us to establish robust causal relationships. Pro-
gram designers nonetheless can draw lessons to improve the efficiency of PMTCT programs
without compromising equity.
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